Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
vorolanib (EYP-1901) / EyePoint Pharma
DAVIO2, NCT05381948: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)	Completed	2	160	US	Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph, Eylea	EyePoint Pharmaceuticals, Inc.	Wet Age-related Macular Degeneration	11/23	04/24
NCT05383209: Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)	Completed	2	77	US	EYP-1901, Vorolanib, Sham IVT	EyePoint Pharmaceuticals, Inc.	Nonproliferative Diabetic Retinopathy	02/24	05/24
VERONA, NCT06099184: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)	Recruiting	2	25	US	EYP-1901, Vorolanib, Aflibercept 2Mg/0.05Ml Inj,Oph, Eylea	EyePoint Pharmaceuticals, Inc.	Diabetic Macular Edema	01/25	01/25